DGAP-News

PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA - Seite 2

About PAION
PAION AG is a publicly listed specialty pharmaceutical company developing
and aiming to commercialize innovative drugs to be used in out-patient and
hospital-based sedation, anesthesia and critical care services. PAION's
lead compound is remimazolam, an intravenous, ultra-short-acting and
controllable benzodiazepine sedative/anesthetic drug candidate. Currently,
remimazolam is in active Phase III clinical development for use in
procedural sedation in the U.S., where PAION is focusing all its business
and financial resources on successfully completing its ongoing clinical
development program in procedural sedation. Outside the U.S., PAION has so
far focused on the development of remimazolam in the indication general
anesthesia. Development of remimazolam in the indication intensive care
unit (ICU) sedation is also part of the longer term life-cycle plan for
remimazolam.

PAION is headquartered in Aachen (Germany) with further sites in Cambridge
(United Kingdom) and New Jersey (USA).

PAION's vision is to become an acknowledged "PAIONeer" in sedation and
anesthesia.


PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: [phone]
E-mail: [e-mail]
www.paion.com

Disclaimer:

This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such forward-
looking statements. Considering the risks, uncertainties and other factors
involved, recipients should not rely unreasonably upon these forward-
looking statements. PAION AG has no obligation to periodically update any
such forward-looking statements to reflect future events or developments.


---------------------------------------------------------------------------

21.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange



End of News DGAP News Service
---------------------------------------------------------------------------

532009 21.12.2016